Updates and controversies in the treatment of pancreatic cancer

Kavitha Kosuri, Peter Muscarella, Tanios Bekaii-Saab

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Despite the many advances in oncology over the last few decades, almost all patients with pancreatic cancer eventually die of the disease. Recent advances, however, have led to the development of more effective therapies. In pancreatic cancer, as in many other malignancies, significant progress in the understanding of important molecular processes associated with the development and progression of the disease is helping tailor more effective treatment strategies. Molecularly targeted agents are offering hope for their potential role in helping translate the improved activity of combination chemotherapy into improved survival. This article summarizes the data from studies that established standards of care and others that created controversy, and reviews novel treatment strategies for this intractable disease.

Original languageEnglish (US)
Pages (from-to)47-54
Number of pages8
JournalClinical Advances in Hematology and Oncology
Volume4
Issue number1
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Standard of Care
Combination Drug Therapy
Disease Progression
Therapeutics
Survival
Neoplasms

Keywords

  • Chemotherapy
  • Pancreatic cancer
  • Targeted agents

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Updates and controversies in the treatment of pancreatic cancer. / Kosuri, Kavitha; Muscarella, Peter; Bekaii-Saab, Tanios.

In: Clinical Advances in Hematology and Oncology, Vol. 4, No. 1, 01.01.2006, p. 47-54.

Research output: Contribution to journalArticle

@article{29ee29d8c2934af98f01f8d888130117,
title = "Updates and controversies in the treatment of pancreatic cancer",
abstract = "Despite the many advances in oncology over the last few decades, almost all patients with pancreatic cancer eventually die of the disease. Recent advances, however, have led to the development of more effective therapies. In pancreatic cancer, as in many other malignancies, significant progress in the understanding of important molecular processes associated with the development and progression of the disease is helping tailor more effective treatment strategies. Molecularly targeted agents are offering hope for their potential role in helping translate the improved activity of combination chemotherapy into improved survival. This article summarizes the data from studies that established standards of care and others that created controversy, and reviews novel treatment strategies for this intractable disease.",
keywords = "Chemotherapy, Pancreatic cancer, Targeted agents",
author = "Kavitha Kosuri and Peter Muscarella and Tanios Bekaii-Saab",
year = "2006",
month = "1",
day = "1",
language = "English (US)",
volume = "4",
pages = "47--54",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "1",

}

TY - JOUR

T1 - Updates and controversies in the treatment of pancreatic cancer

AU - Kosuri, Kavitha

AU - Muscarella, Peter

AU - Bekaii-Saab, Tanios

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Despite the many advances in oncology over the last few decades, almost all patients with pancreatic cancer eventually die of the disease. Recent advances, however, have led to the development of more effective therapies. In pancreatic cancer, as in many other malignancies, significant progress in the understanding of important molecular processes associated with the development and progression of the disease is helping tailor more effective treatment strategies. Molecularly targeted agents are offering hope for their potential role in helping translate the improved activity of combination chemotherapy into improved survival. This article summarizes the data from studies that established standards of care and others that created controversy, and reviews novel treatment strategies for this intractable disease.

AB - Despite the many advances in oncology over the last few decades, almost all patients with pancreatic cancer eventually die of the disease. Recent advances, however, have led to the development of more effective therapies. In pancreatic cancer, as in many other malignancies, significant progress in the understanding of important molecular processes associated with the development and progression of the disease is helping tailor more effective treatment strategies. Molecularly targeted agents are offering hope for their potential role in helping translate the improved activity of combination chemotherapy into improved survival. This article summarizes the data from studies that established standards of care and others that created controversy, and reviews novel treatment strategies for this intractable disease.

KW - Chemotherapy

KW - Pancreatic cancer

KW - Targeted agents

UR - http://www.scopus.com/inward/record.url?scp=31744433964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31744433964&partnerID=8YFLogxK

M3 - Article

C2 - 16562370

AN - SCOPUS:31744433964

VL - 4

SP - 47

EP - 54

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 1

ER -